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ABSTRACT: Mesoporous silica nanoparticles (MSNPs)
have garnered a great deal of attention as potential carriers
fortherapeutic payloads. However, achieving triggered drug
release from MSNPs in vivo has been challenging. Here,
we describe the synthesis of stimulus-responsive polymer-
coatedMSNPsandtheloadingoftherapeuticsintoboththe
coreandshelldomains.WecharacterizeMSNPdrug-eluting
properties in vitro and demonstrate that the polymer-coated
MSNPs release doxorubicin in response to proteases pre-
sent at a tumor site in vivo, resulting in cellular apoptosis.
These results demonstrate the utility of polymer-coated
nanoparticlesinspeciﬁcallydeliveringanantitumorpayload.
N
anotechnology has the potential to impact many long-
standing challenges in medicine, such as selective drug
delivery and sensitive detection of disease.
14 In recent years,
mesoporous silica nanoparticles (MSNPs) have attracted atten-
tion as a promising component of multimodal nanoparticle sys-
tems.
59 MSNPs are excellent candidates for many biomedical
applications owing to their straightforward synthesis, tunable
poremorphologies,facilefunctionalizationchemistries,low-toxi-
city degradation pathways in the biological milieu, and capacity
to carry disparate payloads (molecular drugs, proteins, other
nanoparticles) within the porous core.
58,1012
Despite their promise, however, recent reports highlight the
potential toxicity of unmodiﬁed MSNPs due to interactions of
surface silanols with cellular membranes.
1316 This toxicity
can be reduced by coating the nanoparticle with a polymer
shell.
5,1721 Polymer shells also provide colloidal stability, han-
dles for chemoligation (targeting moieties) and improved blood
circulation lifetimes, which are crucial for eﬃcient in vivo drug
delivery. Unfortunately, the polymer shell also limits both drug
loading and release from MSNPs.
Inordertoaddress thedrawbacksofcoating,wedevelopedan
MSNPpolymerthatdegradesinresponsetoexternalstimuli.We
explored both physical triggers, such as temperature, and bio-
chemical triggers, such as proteases found in the tumor micro-
environment.Loadingandresponsivedrugreleasewereexplored
using payloads incorporated into the MSNP core as well as the
polymer shell.
In our attempt to coat MSNPs with polymers, we considered
previouslyreportedapproaches,suchasnoncovalentassemblyor
surface-initiated polymerizations techniques.
18,2226 These
methods, however, have limitations. Noncovalent strategies are
prone to colloidal and biological instability, whereas covalent
surface-initiated polymerization approaches typically result in
larger particles and expose the MSNP to harsh reaction condi-
tions.Furthermore,theexistingmethodsdonotprovidetheﬂexi-
bility to allow drug loading in distinct compartments. We there-
fore developed a new strategy (Figure 1a) based on a coreshell
architecture and an aqueous free radical polymerization tech-
nique. We ﬁrst electrostatically adsorb an acrylamide to the
MSNP surface and then utilize the acryl groups to synthesize a
covalentlycross-linkedpoly(ethyleneglycol)(PEG)-basedpoly-
mer shell. The covalent cross-linking can provide addition sta-
bilitytothepolymershell.
2729Thissyntheticstrategyprovidesa
covalent polymer shell without the use of catalysts and surfac-
tants and requires mild conditions compatible with a variety of
potential biomolecular payloads.
MSNPs were synthesized via co-condensation of silicates,
similar to previous reports.
10,30 To coat the anionic surface of
the MSNPs, we used bifunctional N-(3-aminopropyl) methacry-
lamide hydrochloride (APMA). The amino group was electro-
statically bound to thenanoparticle surface,whilethe acrylamide
group was available for radical polymerization. Subsequently, a
covalently cross-linked polymer shell was synthesized at room
temperature by radical polymerization of monomers, including
N-isopropylacrylamide (NIPAm) or poly(ethylene glycol) dia-
crylate (PEGDA). The monomer concentrations during synthe-
siswerekeptlowandinordertoproduceadensepolymershell,it
was necessaryto perform a second polymerization stepto yield a
“double-coated” nanoparticle.
Transmission electron microscopy (TEM) images (Figure 1b
and Figure S1c, Supporting Information) indicated that the
synthesis yielded individually encapsulated MSNPs displaying a
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thin polymeric shell, which is absent on uncoated nanoparticles.
TEMmeasurementsindicatedthatthediametersoftheuncoated
and polymer-coated MSNPs were 70 ( 8 and 94 ( 12 nm,
respectively. Dynamic light scattering measurements showed
that the hydrodynamic diameter of the MSNPs increased upon
addition of single or double pNIPAm-co-PEG (9:1 molar ratio)
shells by ∼2040% (Figure S1, Supporting Information). The
DLS and TEM dataindicatethat this polymer coating procedure
avoids agglomerationof thenanoparticles intothelarger (micro-
meter-scale) aggregates that have been previously observed with
other coating techniques.
22
We next investigated the drug-loading capacity of the poly-
mer-coated MSNPs by comparing the total amount of drug
loaded before and after polymer coating. We chose doxorubicin
(Dox) as a model payload due to its well-characterized spectral
characteristics, its use in chemotherapy, and its aﬃnity for the
negatively charged surface of the silica nanoparticles, which
enhances loading into the MSNP pores.
31 The loading of Dox
in polymer-coated MSNPs was only slightly lower (∼50% of
totalDoxadded)comparedwiththeuncoatedMSNPs(∼60%of
total Dox added) (Figure S3a, Supporting Information). This
suggests that the polymer shell does not reduce the drug loading
capacity of MSNPs as drastically as other reported polymer
shellMSNP systems, which is an additional advantage of our
technique over previously reported coating methods.
17,32 We
also observed that the polymer shell provided colloidal stability
at low pH and prevented aggregation of the MSNPs, which
are prone to interparticle hydrogen bonding (Figure S4a, Sup-
porting Information). The synthesis allows facile incorporation
of comonomers that can add additional functionality to the shell
(Figure S4b, Supporting Information).
To assess the in vitro safety and biocompatibility of the
polymer-coated MSNPs, we analyzed mitochondrial activity of
HeLa cells following incubation with diﬀering concentrations of
polymer-coated MSNPs. No signiﬁcant in vitro cytotoxicity was
observed for nanoparticle concentrations of0.011 mg/mL and
with a range of PEG content in the polymer shell (Figure 1c).
By contrast, the uncoated MSNPs exhibited signs of cytotoxicity
at concentrations of 1 mg/mL.
13,33
To study the biological traﬃcking of the polymer-coated
MSNPs, the outer polymer shell was tagged following polymer-
ization with the near-infrared (near-IR) dye Vivo Tag 680. For
this formulation, the inner shell consisted of PEGDA and the
outer shell was a copolymer of 10 mol % APMA with PEGDA.
The dye was conjugated to the free amine side chains on the
APMA comonomer. Labeled MSNPs were used to study blood
circulation properties in vivo and cellular uptake of the nanopar-
ticles in vitro. Compared with uncoated MSNPs, PEGylated
MSNPs have been shown to possess a longer blood-circulation
lifetime and lower excretion of degradation products in the
urine.
14 In the present work, increasing the mole percent of
PEG from 2 to 90 in the polymer shell increased the circulation
lifetime of MSNPs, measured by quantifying Vivo Tag 680
ﬂuorescence in capillary blood draws (Figure 1d). Cellular
uptake studies (Figure 1e) conﬁrmed that the 90 mol % PEG-
coated MSNP formulation (PEGMSNPs) was internalized by
HeLa cells after 4 h of incubation.
In addition to providing colloidal stability, functional groups
for chemical ligation, and improved biocompatibility and blood
circulation lifetimes, the polymer shell can be used to impart
stimuli responsive characteristics to MSNPs. Stimulus-respon-
sive nanoparticles have been shown to be extremely useful for
controlled drug release.
17,34,35 These systems overcome several
current delivery challenges in therapy because they can be
utilized for sustained drug delivery and co-delivery of multiple
drugs with distinct release proﬁles. In this work, we engineered
theselong-circulating, biocompatible polymer-coated MSNPs to
respond to temperature and the biological microenvironment
(protease) for controlled drug delivery.
The thermally responsive system was synthesized from NI-
PAmPEG (9:1)-coated MSNPs, and doxorubicin was used
as the test drug. It has been shown that pNIPAm, which possesses
alowercriticalsolutiontemperature(LCST)of∼31 C,canprovide
temperature-triggered release of drugs from various nanoparticles.
35
Consistent with these prior results, at temperatures greater than the
LCST(37 C),about50%moreDoxwasreleasedwithintheﬁrst2h
of incubation, compared with the same formulation maintained at
room temperature (Figure 2a). By comparison, uncoated MSNPs
released the same quantity of Dox at either temperature.
We further investigated the inﬂuence of the polymer shell on
the drug release proﬁles from MSNPs in which the drug was
loaded in either the inorganic core or the polymer shell of the
nanoparticle. To compare these two loading strategies, we mea-
sured the drug loading eﬃciencies and characterized the drug
release proﬁles in core-loaded and shell-loaded PEGMSNPs.
For the core-loaded PEGMSNPs, doxorubicin was loaded in
the MSNPs with a single PEGDA shell and a second covalent
polymer shell (PEG-co-APMA) was synthesized after drug load-
ing to provide a diﬀusion barrier. For the shell-loaded PEG
MSNPs, Dox was loaded after the synthesis of the second PEG-
co-APMA shell. Excess unloaded Dox was removed by centrifu-
gation of the loaded nanoparticles. Compared with uncoated
MSNPs, the loading eﬃciency of the polymer-coated MSNPs
wasreducedsomewhatbutwasnotdramaticallydiﬀerent(p=0.043
by ANOVA tukey analysis, Figure S3b, Supporting Information).
Interestingly, the polymer-coated MSNPs held comparable
amounts of Dox in either core- or shell-loaded formulations
(FigureS3b,SupportingInformation).Core-loadedPEGMSNPs
displayed the slowest rate of Dox release; only ∼20% of the
Figure 1. Polymer-coated MSNPs: (a) Synthetic scheme for the
polymer coating of MSNPs. (b) TEM micrographs of uncoated and
PEG-coated MSNPs. Scale bar is 20 nm. (c) In vitro viability of HeLa
cells in the presence of uncoated MSNPs and polymer-coated MSNPs
(n = 3). (d) In vivo circulation lifetime of polymer-coated MSNPs after
tail vein injections in Swiss Webster mice (n = 3). (e) Cellular uptake of
PEGMSNPs by HeLa cells. Red, Vivo Tag 680 conjugated to the
polymer shell; Blue, DAPI. Scale bar is 10 μm.19584 dx.doi.org/10.1021/ja206998x |J. Am. Chem. Soc. 2011, 133, 19582–19585
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drug was released after 24 h (Figure 2b). The shell-loaded
PEGMSNPs released ∼40% of the drug in the ﬁrst 2 h
and ∼60% after 24 h. Initially, the uncoated MSNPs released
Dox at a slightly slower rate compared with the shell-loaded
PEGMSNPs but a larger total quantity of drug was released
after 24 h (∼85% vs 63% of the loaded drug, respectively).
Theinitialrapidrateofdrugreleasefromtheshell-loadedPEG
MSNPs compared with the uncoated MSNPs suggested that
Dox was loaded both in the core and the polymer shell in this
PEGMSNP formulation. The initial relatively rapid rate of
release observed is attributed to diﬀusion of Dox loaded in the
PEG shell. The release of Dox from a formulation in which the
drug was loaded exclusively in the MSNP core and then coated
with a polymer shell (core-loaded PEGMSNPs) was much
slower. Thus, the polymer shell provides a facile means to tune
thedrugreleaseproﬁle.Thecore-loadedPEGMSNPsdisplaya
veryslowdrugreleaseproﬁlewithnopremature(“burst”) release,
both desirable attributes for a “triggered” formulation designed
torespondtospeciﬁctumoralextracellularsignatures,suchaspro-
teases. For instance, it is known that matrix metalloproteinases
(MMPs),whichhavetheabilitytodegradetheextracellularmatrix,
are up-regulated in tumor environments because of secretion by
rapidly dividing cancer cells and stromal cells.
34
We therefore investigated whether MMP proteases could
trigger drug release from the polymer-coated MSNPs. For the
protease-sensitive polymer shell, we used PEGDApeptide
macromer possessing MMP substrate polypeptides with a highly
degradable (HD-MMP) and a low-degradability (LD-MMP)
sequence.
36 We investigated protease-triggered drug release
from core-loaded or shell-loaded PEGpeptide (HD-MMP
and LD-MMP)-coated MSNPs by analyzing the chemotoxicity
ofDoxreleasedduring48hofincubationwith3T3-J2ﬁbroblasts.
In a typical experiment, 3T3-J2 ﬁbroblasts were incubated
with nanoparticles and assayed for cell viability using alamarBlue
48 h later. We observed high levels of Dox-induced chemotoxi-
city (∼1520% cell viability) in all shell-loaded nanoparticles,
regardless of their polymeric shell (PEGDA, LD-MMP, or
HD-MMP; Figure 2c). This level of chemotoxicity was compar-
abletoDox-loadeduncoatedMSNPsandfreedrug(forthesame
quantity of Dox administered) and is in accordance with the fast
drug release proﬁle of shell-loaded and uncoated MSNPs. In
contrast, the Dox-induced chemotoxicity of core-loaded
PEGMSNPs was dependent on polymer shell composition. Low
level of chemotoxicity (∼6070% cell viability) was observed for
core-loaded PEGMSNP and LD-PEGMSNPs, suggesting that
in 48 h, the quantity of drug released from low- and nondegradable
PEG nanoparticles was limited. Residual levels of drug release from
LD-PEGMSNPs is attributed to leaching of the drug and not
cleavageofthePEGpeptideshell.Incontrast,thechemotoxicityof
core-loaded HD-PEGMSNPs was high (30% cell viability), sig-
nifying that rapid Dox release resulted from cleavage of the
PEGpeptide shell by endogenous MMPs in the cellular medium.
Indeed, blocking the endogenous MMPs secreted by the ﬁbroblasts
with the inhibitor batimastat lowered the chemotoxicity of the HD-
MMPMSNPs (Figure S5b, Supporting Information). These re-
sults demonstrate that protease-triggered release can be achieved
with polymer-coated MSNPs. The various polymer coatings on
MSNPs thus allowed both spatial control over loading and temporal
control over release of Dox in vitro.
Finally, we conducted in vivo studies in subcutaneous xeno-
graft mouse models to test the protease-triggered release of Dox
fromthepolymer-coatedMSNPs. Weinjectedahumansarcoma
cell line (HT-1080), known to have elevated levels of MMPs,
37 sub-
cutaneously in ﬂanks of immune-compromised mice (Figure 3a).
Two weeks later, core-loaded HD-PEGMSNPs, core-loaded
PEGMSNPs, uncoated MSNPs and Dox-loaded uncoated
MSNPs were normalized to a drug concentration of 2 mg/kg and
injectedintowell-deﬁnedtumors.Thetumorswereremovedafter60
h and analyzed for Dox-induced apoptosis by measurement of
TUNEL staining and caspase levels (Figure 3b,c). Tumor cell
lysates were analyzed for apoptosis markers procaspase-9 and
cleaved caspase-9 by immunoblotting (Figure 3b). While the
GAPDH levels were similar for each sample, exposure to the
core-loaded HD-PEGMSNP formulation and Dox-loaded un-
coated MSNPs generated higher levels of the caspases. In
contrast, the core-loaded PEGMSNPs showed lower caspase
levels, similar to those of saline-treated samples. Interestingly,
core-loaded PEGMSNPs generated lower levels of caspases
compared with unloaded uncoated MSNPs. This ﬁnding is in
accordance within vitro studies suggesting that the polymer shell
reduces inherent nanoparticle toxicity. TUNEL staining of the
tumor sections (Figure 3c) indicated that the core-loaded HD-
PEGMSNPs mediated signiﬁcantly higher Dox-induced cell
death compared with PEGMSNPs. Taken together, these
resultsshowthatthecore-loadedMSNPswithanMMP-sensitive
PEG shell exhibit higher Dox-induced chemotoxicity than those
with a non-MMP-sensitive PEG shell. We conclude that this
higher chemotoxicity is due to eﬃcient release of Dox triggered
bytheMMPsinvivo.Thissystemtakesadvantageoftheabilityof
thePEGpolymershelltoreducetheinherenttoxicityofMSNPs,
and incorporation of a protease-cleavable moiety achieves trig-
gered delivery that accelerates tumor-localized drug release.
Figure 2. Controlling drug release from polymer-coated MSNPs: (a)
Temperature-triggered release of doxorubicin from pNIPAM-co-PEG
coated MSNPs. Inset shows release after 2 h. (b) Doxorubicin release
proﬁle in PBS at 37  C for uncoated MSNPs and core-loaded and shell-
loaded PEGMSNPs. (c) Dox-induced chemotoxicity on J2-3T3 ﬁbro-
blasts from MMP-degradable PEGMSNPs (HD, highly degradable;
LD,lowdegradability),PEGMSNPs,andDox-loadedMSNPs(MSNP-
Dox) (n = 3).19585 dx.doi.org/10.1021/ja206998x |J. Am. Chem. Soc. 2011, 133, 19582–19585
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In conclusion, we reported a facile and versatile method for
coating MSNPs with responsive, biocompatible polymers. The
polymer shell not only enables functionalization of the MSNPs
with various ligands but also provides colloidal stability, tem-
perature sensitivity, imaging capability, longer blood circulation,
high payload capacity, and the opportunity to tune the loading
and release of small molecules. Furthermore, we demonstrated
that the polymer shell can be used to achieve predetermined,
temporal control over drug release; the appropriately modiﬁed
polymer can be responsive to endogenous proteases allowing
triggered, localized drug release in vitro and in vivo. The polymer
coatings also allow spatial control of payload loading within the
nanostructure of the MSNP. This capacity is important for
applications requiring multiple payloads with speciﬁcally timed
release proﬁles from a single nanoparticle system.
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